Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.56 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.47 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.47 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997372 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL31387861 | 0.96 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL19088576 | 0.87 | FFAR4 (0.51) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL25795117 | 0.86 | FFAR4 (0.50) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL10104444 | 0.84 | ALDH1A1 (0.69) | ALDH1A1GAALMNAKDM4ESRPK1 | |
| SCHEMBL13179908 | 0.84 | HTR3A (0.58) | ALDH1A1MAPTTHRBLMNAKDM4E | |
| SCHEMBL8261938 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL13997364 | 0.82 | SCN10A (0.46) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL330331 | 0.80 | ALDH1A1 (0.73) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL28001286 | 0.80 | MAPT (0.49) | ALDH1A1MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610317-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9233136-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9133115-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785378-B2 | Macrocyclic peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140113890-A1 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | ALDH1A1 764/4885MAPT 2288/4885MEN1 1579/4885 |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, ZC3HAV1L | ALDH1A1 3885/4885MAPT 4060/4885MEN1 4712/4885 |
| US-20140113890-A1 | NEW 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, ZC3HAV1L | ALDH1A1 4204/4885MAPT 4391/4885MEN1 3771/4885 |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | ALDH1A1 4010/4885MAPT 4499/4885MEN1 3246/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | ALDH1A1 2329/4885MAPT 1370/4885MEN1 2006/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | ALDH1A1 748/4885MAPT 758/4885MEN1 549/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ALDH1A1 340/4885MAPT 2469/4885MEN1 2142/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | ALDH1A1 362/4885MAPT 2415/4885MEN1 2098/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | ALDH1A1 140/4885MAPT 3082/4885MEN1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.